Therapeutic advances in functional gastrointestinal disease: irritable bowel syndrome.

Therapeutic Advances in Gastroenterology
Alexandru GamanBraden Kuo

Abstract

Reported prevalence rates of irritable bowel syndrome (IBS) are between 8% to 20% in the US general population with an average medical expenditure of US$1.35 billion direct and US$205 million indirect costs. Current pathophysiologic theories are based on abnormalities of both the brain and gut, thus setting a new stage for current and future therapeutic approaches. There are numerous treatment options in IBS acting centrally and peripherally by influencing motility and visceral sensitivity. Clinical evidence is variable; however, newer emerging treatments are being evaluated using better-designed clinical trials. Accurate assessment of IBS drug efficacy is still hampered by heterogeneity of the IBS population. Novel methods such as pharmacogenomics or brain imaging may be helpful in the future to better understand and characterize IBS patient subtypes, and this in turn will lead to more specific and efficient therapeutic options. Patient subpopulation measurement of side effects is also a clinical challenge and further understanding could improve treatment efficacy enhancing the patient compliance.

References

Aug 1, 1992·Mayo Clinic Proceedings·M J VassalloA C Haddad
Sep 1, 1990·Proceedings of the National Academy of Sciences of the United States of America·W A BanksA J Kastin
Jun 1, 1993·Digestive Diseases and Sciences·F AwoutersP A Janssen
Nov 1, 1994·Comparative Biochemistry and Physiology. Part A, Physiology·G BjörnhagW von Engelhardt
Mar 1, 1996·Neurogastroenterology and Motility : the Official Journal of the European Gastrointestinal Motility Society·T LemboE Mayer
Apr 1, 1996·Naunyn-Schmiedeberg's Archives of Pharmacology·Y NagakuraK Miyata
Jun 11, 1999·Clinical Therapeutics·S RomanoK Sundell
Jul 8, 1999·Proceedings of the National Academy of Sciences of the United States of America·X Q Shu, L M Mendell
Feb 29, 2000·British Journal of Pharmacology·M ToulouseL Buéno
Sep 30, 2000·Neurogastroenterology and Motility : the Official Journal of the European Gastrointestinal Motility Society·F MulèR Serio
Jul 5, 2001·Neurogastroenterology and Motility : the Official Journal of the European Gastrointestinal Motility Society·L OnoriM Tonini
Sep 25, 2001·The American Journal of Gastroenterology·T LemboUNKNOWN Lotronex Investigator Team
Feb 8, 2002·World Journal of Gastroenterology : WJG·Hong WangJin-Shan Zhang
Feb 13, 2002·Clinical Nurse Specialist CNS·Rebecca WassemJanet Racine
Feb 28, 2002·The Journal of Pharmacology and Experimental Therapeutics·Shiho OkanoNobuhiro Inatomi
Jul 30, 2002·Alimentary Pharmacology & Therapeutics·A V EmmanuelM A Kamm
Jan 31, 2003·Gastroenterology·Francis CreedUNKNOWN North of England IBS Research Group
Mar 28, 2003·American Journal of Physiology. Gastrointestinal and Liver Physiology·Luciano OnoriMarcello Tonini
Apr 8, 2003·Drugs·Vincenzo StanghelliniRoberto Corinaldesi
Jun 24, 2003·The American Journal of Gastroenterology·Henry P ParkmanUNKNOWN Functional Constipation Study Investigators
Jul 9, 2003·Neurogastroenterology and Motility : the Official Journal of the European Gastrointestinal Motility Society·J FioramontiL Bueno
Sep 13, 2003·British Journal of Clinical Pharmacology·Nicholas J Talley
Sep 27, 2003·Alimentary Pharmacology & Therapeutics·J M InadomiD Bjorkman
Oct 25, 2003·American Journal of Physiology. Gastrointestinal and Liver Physiology·Bi-Guang TuoJon I Isenberg
Nov 5, 2003·Expert Opinion on Pharmacotherapy·Emeran A Mayer, Sylvie Bradesi
Mar 24, 2004·British Journal of Pharmacology·Alessandro LecciCarlo Alberto Maggi
Apr 15, 2004·Toxicology and Applied Pharmacology·Kalina Venkova, Beverley Greenwood-Van Meerveld

❮ Previous
Next ❯

Citations

Jun 22, 2011·The American Journal of Gastroenterology·Susan A GaylordWilliam E Whitehead
May 23, 2018·Voprosy kurortologii, fizioterapii, i lechebnoĭ fizicheskoĭ kultury·E V SevostyanovaV Y Polyakov
Mar 31, 2012·The Nurse Practitioner·Diana L Wadlund

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.